Literature DB >> 9387199

Spontaneous erythroid colony formation as the clue to an underlying myeloproliferative disorder in patients with Budd-Chiari syndrome or portal vein thrombosis.

V De Stefano1, L Teofili, G Leone, J J Michiels.   

Abstract

Budd-Chiari syndrome is a severe disease characterized by occlusion of large hepatic veins leading to death if untreated. Using the classical criteria for the diagnosis of polycythemia vera (PV), essential thrombocythemia (ET), and idiopathic myelofibrosis (IMF), overt PV was the underlying cause in about 10% of the cases and ET or IMF in only a very few. Using spontaneous endogenous erythroid colony (EEC) formation in vitro and/or bone marrow biopsies, a primary myeloproliferative disorder (PMD) was present in 78% of the patients with apparently idiopathic Budd-Chiari syndrome and in about half of the patients with portal, splenic, and/or mesenteric vein thrombosis. The diagnoses in 40 reported cases with hepatic vein thrombosis and spontaneous EEC were overt PV in 25 and latent unclassified PMD in 15 patients. The diagnoses of 40 reported cases with splanchnic vein thrombosis and spontaneous EEC were overt PV in 12, ET in 2, IMF in 2, and latent unclassified PMD with the presence of EEC in 24 patients. Thrombocytosis as a manifestation of myeloproliferative disease was recorded in 34 of 80 (42.5%) patients with spontaneous EEC and Budd-Chiari syndrome or portal vein thrombosis. Thrombocythemia was present in 15 of 41 patients with a proven and in 19 of 39 patients with a latent myeloproliferative disorder. Patients with hepatic vein or splanchnic vein thrombosis associated with a PMD are predominantly females younger than 45. It is concluded that both spontaneous EEC and histopathology from bone marrow biopsy provide specific information as sensitive clues to the diagnosis of all variants of overt and latent myeloproliferative disorders. The association of hepatic and splanchnic vein thrombosis and PMD is not fully understood. Therapeutic options of Budd-Chiari syndrome include anticoagulation with heparin, fibrinolysis followed by oral anticoagulation, and appropriate treatment of the underlying PMD. In case of failure, invasive options include local procedures such as angioplasty or stenting, venous decompression by portal-systemic shunts, or liver transplantation.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9387199     DOI: 10.1055/s-2007-996117

Source DB:  PubMed          Journal:  Semin Thromb Hemost        ISSN: 0094-6176            Impact factor:   4.180


  21 in total

Review 1.  Splanchnic vein thrombosis: clinical presentation, risk factors and treatment.

Authors:  Valerio De Stefano; Ida Martinelli
Journal:  Intern Emerg Med       Date:  2010-06-08       Impact factor: 3.397

2.  Patients with polycythemia vera and essential thrombocythemia with prior malignancy do not have significantly worse outcome.

Authors:  Mohamad Cherry; Marylou Cardenas-Turanzas; Hannah Pham; Hagop Kantarjian; Jorge Cortes; Sherry Pierce; Lingsha Zhou; Srdan Verstovsek
Journal:  Leuk Res       Date:  2013-08-14       Impact factor: 3.156

3.  Splanchnic venous thrombosis driven by a constitutively activated JAK2 V617F philadelphia-negative myeloproliferative neoplasm: a case report.

Authors:  Musa Waiswa; Emmanuel Seremba; Ponsiana Ocama; Henry Ddungu; Keneth Opio; Clement Okello; Timothy O'shea; Madeleine Verhovsek; Richard Mutyabule
Journal:  Afr Health Sci       Date:  2014-12       Impact factor: 0.927

4.  Low frequency of V617F mutation in JAK2 gene in Indian patients with hepatic venous outflow obstruction and extrahepatic portal venous obstruction.

Authors:  Praveer Rai; Pankaj Kumar; Swapnil Mishra; Rakesh Aggarwal
Journal:  Indian J Gastroenterol       Date:  2016-09-16

Review 5.  What is the standard treatment in essential thrombocythemia.

Authors:  Tiziano Barbui
Journal:  Int J Hematol       Date:  2002-08       Impact factor: 2.490

6.  JAK2 (V617F) Positive Latent Myeloproliferative Neoplasm Presenting with Splanchnic Vein Thrombosis.

Authors:  Amandeep Salhotra; Thein H Oo
Journal:  Indian J Hematol Blood Transfus       Date:  2012-12-18       Impact factor: 0.900

7.  JAK2V617F mutation in patients with portal vein thrombosis.

Authors:  Yusuf Bayraktar; Ozgur Harmanci; Yahya Büyükasik; Ali Ibrahim Shorbagi; Aysegul Hasegeli Sungur; Cemaliye Akyerli Boylu; Aytemiz Gürgey; Ferhun Balkanci
Journal:  Dig Dis Sci       Date:  2008-03-15       Impact factor: 3.199

Review 8.  Etiology and consequences of thrombosis in abdominal vessels.

Authors:  Yusuf Bayraktar; Ozgur Harmanci
Journal:  World J Gastroenterol       Date:  2006-02-28       Impact factor: 5.742

9.  JAK2V617F mutation in patients with splanchnic vein thrombosis.

Authors:  Sandra Guerra Xavier; Telma Gadelha; Glicínia Pimenta; Angela Maria Eugenio; Daniel Dias Ribeiro; Fernanda Mendes Gomes; Martin Bonamino; Ilana Renault Zalcberg; Nelson Spector
Journal:  Dig Dis Sci       Date:  2009-08-19       Impact factor: 3.199

10.  Risk factors of thrombosis in abdominal veins.

Authors:  Amit-Kumar Dutta; Ashok Chacko; Biju George; Joseph Anjilivelil Joseph; Sukesh Chandran Nair; Vikram Mathews
Journal:  World J Gastroenterol       Date:  2008-07-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.